25 XP   0   0   10

Hepion Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Hepion Pharmaceuticals Inc together

PenkeI guess you are interested in Hepion Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hepion Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hepion Pharmaceuticals Inc

I send you an email if I find something interesting about Hepion Pharmaceuticals Inc.

Quick analysis of Hepion Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Hepion Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
25.0%

What is your share worth?

Current worth
$3.73
Expected worth in 1 year
$-6.21
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-9.94
Return On Investment
-770.2%

For what price can you sell your share?

Current Price per Share
$1.29
Expected price per share
$0 - $2.8999
How sure are you?
50%

1. Valuation of Hepion Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$1.29

Intrinsic Value Per Share

$-126.08 - $-76.70

Total Value Per Share

$-122.36 - $-72.97

2. Growth of Hepion Pharmaceuticals Inc (5 min.)




Is Hepion Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$16.1m$78.1m-$42.5m-119.7%

How much money is Hepion Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$9.5m-$11.9m$2.4m25.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Hepion Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#475 / 1010

Most Revenue
#960 / 1010

Most Profit
#864 / 1010

Most Efficient
#402 / 1010

What can you expect buying and holding a share of Hepion Pharmaceuticals Inc? (5 min.)

Welcome investor! Hepion Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Hepion Pharmaceuticals Inc.

What can you expect buying and holding a share of Hepion Pharmaceuticals Inc?

First you should know what it really means to hold a share of Hepion Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Hepion Pharmaceuticals Inc is $1.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hepion Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hepion Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.73. Based on the TTM, the Book Value Change Per Share is $-2.48 per quarter. Based on the YOY, the Book Value Change Per Share is $-2.50 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hepion Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.43-188.1%-2.22-171.7%-2.07-160.6%-1.47-114.0%-1.16-90.3%
Usd Book Value Change Per Share-2.35-182.5%-2.48-192.6%-2.50-193.8%0.1310.3%0.097.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.064.4%0.075.7%
Usd Total Gains Per Share-2.35-182.5%-2.48-192.5%-2.50-193.8%0.1914.6%0.1713.1%
Usd Price Per Share4.99-4.14-0.88-2.39-1.90-
Price to Earnings Ratio-0.51--0.49--0.63--0.91--0.61-
Price-to-Total Gains Ratio-2.12--1.00--0.09--17.23--4.02-
Price to Book Ratio1.34-0.90-0.27-0.76-0.14-
Price-to-Total Gains Ratio-2.12--1.00--0.09--17.23--4.02-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.29
Number of shares775
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.06
Usd Book Value Change Per Share-2.480.13
Usd Total Gains Per Share-2.480.19
Gains per Quarter (775 shares)-1,924.92146.41
Gains per Year (775 shares)-7,699.68585.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11-7701-7710175411576
22-15401-154103498221162
33-23102-2311052412331748
44-30802-3081069816442334
54-38503-3851087320552920
65-46203-46210104724673506
76-53904-53910122228784092
87-61605-61610139632894678
98-69305-69310157137005264
109-77006-77010174641115850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%2.039.00.04.9%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%14.026.00.035.0%14.027.00.034.1%
Dividend per Share1.00.03.025.0%6.00.06.050.0%9.00.011.045.0%10.00.030.025.0%10.00.031.024.4%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%16.024.00.040.0%16.025.00.039.0%

Fundamentals of Hepion Pharmaceuticals Inc

About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Fundamental data was last updated by Penke on 2024-04-11 10:39:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Hepion Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hepion Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y--436.8%+436.8%
10Y--597.3%+597.3%
1.1.2. Return on Assets

Shows how efficient Hepion Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
  • -42.1% Return on Assets means that Hepion Pharmaceuticals Inc generated $-0.42 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hepion Pharmaceuticals Inc:

  • The MRQ is -42.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -25.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-42.1%TTM-25.8%-16.3%
TTM-25.8%YOY-13.7%-12.1%
TTM-25.8%5Y-16.4%-9.5%
5Y-16.4%10Y-81.5%+65.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-42.1%-13.3%-28.8%
TTM-25.8%-12.8%-13.0%
YOY-13.7%-11.6%-2.1%
5Y-16.4%-13.8%-2.6%
10Y-81.5%-15.6%-65.9%
1.1.3. Return on Equity

Shows how efficient Hepion Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
  • -65.1% Return on Equity means Hepion Pharmaceuticals Inc generated $-0.65 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hepion Pharmaceuticals Inc:

  • The MRQ is -65.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -36.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-65.1%TTM-36.5%-28.7%
TTM-36.5%YOY-16.2%-20.2%
TTM-36.5%5Y-39.9%+3.4%
5Y-39.9%10Y-59.6%+19.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-65.1%-16.9%-48.2%
TTM-36.5%-16.1%-20.4%
YOY-16.2%-14.9%-1.3%
5Y-39.9%-19.3%-20.6%
10Y-59.6%-20.1%-39.5%

1.2. Operating Efficiency of Hepion Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hepion Pharmaceuticals Inc is operating .

  • Measures how much profit Hepion Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y--486.2%+486.2%
10Y--628.4%+628.4%
1.2.2. Operating Ratio

Measures how efficient Hepion Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y-5.679-5.679
10Y-7.823-7.823

1.3. Liquidity of Hepion Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.32 means the company has $3.32 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 3.322. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.480. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.322TTM5.480-2.158
TTM5.480YOY9.616-4.136
TTM5.4805Y9.694-4.214
5Y9.69410Y6.758+2.937
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3223.863-0.541
TTM5.4804.169+1.311
YOY9.6165.337+4.279
5Y9.6946.122+3.572
10Y6.7586.434+0.324
1.3.2. Quick Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.01 means the company can pay off $3.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 3.012. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.400. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.012TTM3.400-0.388
TTM3.400YOY6.097-2.697
TTM3.4005Y8.365-4.965
5Y8.36510Y6.011+2.354
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0123.504-0.492
TTM3.4003.991-0.591
YOY6.0975.371+0.726
5Y8.3656.088+2.277
10Y6.0116.395-0.384

1.4. Solvency of Hepion Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hepion Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hepion Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.35 means that Hepion Pharmaceuticals Inc assets are financed with 35.4% credit (debt) and the remaining percentage (100% - 35.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.354. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.244. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.354TTM0.244+0.110
TTM0.244YOY0.137+0.107
TTM0.2445Y0.255-0.010
5Y0.25510Y1.985-1.731
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3540.339+0.015
TTM0.2440.337-0.093
YOY0.1370.271-0.134
5Y0.2550.368-0.113
10Y1.9850.388+1.597
1.4.2. Debt to Equity Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 54.7% means that company has $0.55 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.547. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.337. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.547TTM0.337+0.210
TTM0.337YOY0.161+0.176
TTM0.3375Y0.944-0.607
5Y0.94410Y1.108-0.164
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5470.392+0.155
TTM0.3370.403-0.066
YOY0.1610.335-0.174
5Y0.9440.427+0.517
10Y1.1080.461+0.647

2. Market Valuation of Hepion Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Hepion Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.51 means the investor is paying $-0.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hepion Pharmaceuticals Inc:

  • The EOD is -0.133. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.514. Based on the earnings, the company is expensive. -2
  • The TTM is -0.490. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.133MRQ-0.514+0.381
MRQ-0.514TTM-0.490-0.024
TTM-0.490YOY-0.633+0.142
TTM-0.4905Y-0.907+0.417
5Y-0.90710Y-0.608-0.299
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.133-2.300+2.167
MRQ-0.514-2.656+2.142
TTM-0.490-2.718+2.228
YOY-0.633-4.145+3.512
5Y-0.907-6.258+5.351
10Y-0.608-6.315+5.707
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hepion Pharmaceuticals Inc:

  • The EOD is -0.125. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.482. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.690. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.125MRQ-0.482+0.357
MRQ-0.482TTM-0.690+0.208
TTM-0.690YOY-0.815+0.125
TTM-0.6905Y-1.164+0.474
5Y-1.16410Y-1.017-0.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.125-2.974+2.849
MRQ-0.482-3.306+2.824
TTM-0.690-3.508+2.818
YOY-0.815-5.613+4.798
5Y-1.164-8.378+7.214
10Y-1.017-8.873+7.856
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hepion Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.34 means the investor is paying $1.34 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Hepion Pharmaceuticals Inc:

  • The EOD is 0.346. Based on the equity, the company is cheap. +2
  • The MRQ is 1.340. Based on the equity, the company is underpriced. +1
  • The TTM is 0.898. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.346MRQ1.340-0.993
MRQ1.340TTM0.898+0.441
TTM0.898YOY0.267+0.631
TTM0.8985Y0.756+0.142
5Y0.75610Y0.137+0.620
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3461.914-1.568
MRQ1.3402.116-0.776
TTM0.8982.097-1.199
YOY0.2672.881-2.614
5Y0.7563.550-2.794
10Y0.1373.936-3.799
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Hepion Pharmaceuticals Inc.

3.1. Institutions holding Hepion Pharmaceuticals Inc

Institutions are holding 17.302% of the shares of Hepion Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Armistice Capital, LLC9.16630.03043976073976070
2023-09-30Vanguard Group Inc3.8157016551200
2023-09-30BlackRock Inc1.9124082954-2798-3.2629
2023-09-30Octagon Capital Advisors LP1.55610.051867500-87500-56.4516
2023-09-30Geode Capital Management, LLC0.8048034909340.0975
2023-09-30State Street Corporation0.361401567600
2023-09-30Susquehanna International Group, LLP0.3374014635-36-0.2454
2023-09-30Morgan Stanley - Brokerage Accounts0.3015013077-10290-44.0365
2023-09-30Advisor Group Holdings, Inc.0.103404484216493.2759
2023-09-30PNC Financial Services Group Inc0.06640287900
2023-09-30Tower Research Capital LLC0.05110.000422161950733.0827
2023-09-30Group One Trading, LP0.00780339-73-17.7184
2023-09-30Wells Fargo & Co0.000602813.7037
2023-09-30Barclays PLC0.000401600
2023-09-30JPMorgan Chase & Co0.00010550
2023-09-30UBS Group AG002-2669-99.9251
2023-09-30SignatureFD, LLC00100
2023-09-30Hanson Mcclain Inc00100
2023-09-30HARBOR INVESTMENT ADVISORY, LLC00100
2023-09-30Global Retirement Partners, LLC.00110
Total 18.48540.0826801843+298396+37.2%

3.2. Funds holding Hepion Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.3977010400500
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.12750.00014890800
2024-02-29Fidelity Extended Market Index0.53850.000223358-113-0.4814
2023-09-30BlackRock Extended Mkt Composite0.33550.00051455200
2024-03-31BlackRock Extended Equity Market K0.29280.00021270050.0394
2024-02-29Fidelity Series Total Market Index0.12570545200
2024-02-29Fidelity Total Market Index0.12150526900
2024-02-29Vifag 2002 SICAV0.11530.0232500000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.08490.0002368200
2023-12-31Northern Trust Extended Eq Market Idx0.07430.0002322500
2023-12-31NT Ext Equity Mkt Idx Fd - L0.07430.0002322500
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.07160310400
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.07160.00013104-100438-97.0022
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.06820.0002295760.2033
2024-02-29Fidelity Nasdaq Composite Index0.04630200700
2024-03-31State St US Extended Mkt Indx NL Cl C0.03860.0002167500
2023-12-31SSgA U.S. Extended Market Index Class I0.03860.0002167500
2024-02-29Spartan Total Market Index Pool E0.03850167000
2024-03-31Extended Equity Market Fund M0.03610.00021567-3-0.1911
2024-02-29Vanguard U.S. Eq Idx £ Acc0.0310134300
Total 5.72850.0257248478-100543-40.5%

3.3. Insider Transactions

Insiders are holding 0.387% of the shares of Hepion Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-27Peter WijngaardBUY25003.05
2023-11-24Peter WijngaardBUY25003.09
2023-09-19Peter WijngaardBUY10005.64
2023-09-18Robert T FosterBUY16005.6
2023-09-15Peter WijngaardBUY20005.6
2023-09-15Robert T FosterBUY16005.4

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Hepion Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.355-2.484+5%-2.500+6%0.133-1876%0.095-2579%
Book Value Per Share--3.7255.488-32%12.960-71%8.694-57%4.624-19%
Current Ratio--3.3225.480-39%9.616-65%9.694-66%6.758-51%
Debt To Asset Ratio--0.3540.244+45%0.137+158%0.255+39%1.985-82%
Debt To Equity Ratio--0.5470.337+62%0.161+240%0.944-42%1.108-51%
Dividend Per Share---0.000-100%0.001-100%0.056-100%0.073-100%
Eps---2.427-2.215-9%-2.072-15%-1.470-39%-1.165-52%
Free Cash Flow Per Share---2.590-1.658-36%-1.604-38%-1.188-54%-0.972-62%
Free Cash Flow To Equity Per Share---2.590-1.130-56%-1.907-26%0.215-1307%0.144-1901%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---76.699--------
Intrinsic Value_10Y_min---126.081--------
Intrinsic Value_1Y_max---4.443--------
Intrinsic Value_1Y_min---7.358--------
Intrinsic Value_3Y_max---15.822--------
Intrinsic Value_3Y_min---26.809--------
Intrinsic Value_5Y_max---30.179--------
Intrinsic Value_5Y_min---51.262--------
Market Cap5595607.200-287%21645023.20023362656.426-7%24291778.624-11%20785372.899+4%13455522.298+61%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.346-287%1.3400.898+49%0.267+401%0.756+77%0.137+879%
Pe Ratio-0.133+74%-0.514-0.490-5%-0.633+23%-0.907+76%-0.608+18%
Price Per Share1.290-287%4.9904.142+20%0.877+469%2.391+109%1.901+162%
Price To Free Cash Flow Ratio-0.125+74%-0.482-0.690+43%-0.815+69%-1.164+142%-1.017+111%
Price To Total Gains Ratio-0.548+74%-2.119-1.003-53%-0.089-96%-17.233+713%-4.023+90%
Quick Ratio--3.0123.400-11%6.097-51%8.365-64%6.011-50%
Return On Assets---0.421-0.258-39%-0.137-67%-0.164-61%-0.815+94%
Return On Equity---0.651-0.365-44%-0.162-75%-0.399-39%-0.596-8%
Total Gains Per Share---2.355-2.484+5%-2.500+6%0.189-1346%0.168-1499%
Usd Book Value--16158757.00035560925.000-55%78142317.250-79%46305634.200-65%24355021.525-34%
Usd Book Value Change Per Share---2.355-2.484+5%-2.500+6%0.133-1876%0.095-2579%
Usd Book Value Per Share--3.7255.488-32%12.960-71%8.694-57%4.624-19%
Usd Dividend Per Share---0.000-100%0.001-100%0.056-100%0.073-100%
Usd Eps---2.427-2.215-9%-2.072-15%-1.470-39%-1.165-52%
Usd Free Cash Flow---11233660.000-8328555.250-26%-8699723.000-23%-5940814.400-47%-4608791.750-59%
Usd Free Cash Flow Per Share---2.590-1.658-36%-1.604-38%-1.188-54%-0.972-62%
Usd Free Cash Flow To Equity Per Share---2.590-1.130-56%-1.907-26%0.215-1307%0.144-1901%
Usd Market Cap5595607.200-287%21645023.20023362656.426-7%24291778.624-11%20785372.899+4%13455522.298+61%
Usd Price Per Share1.290-287%4.9904.142+20%0.877+469%2.391+109%1.901+162%
Usd Profit---10526946.000-9557360.250-9%-11981214.500+14%-6823374.650-35%-5054788.775-52%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---2.355-2.484+5%-2.500+6%0.189-1346%0.168-1499%
 EOD+3 -5MRQTTM+6 -25YOY+6 -255Y+5 -2610Y+7 -24

4.2. Fundamental Score

Let's check the fundamental score of Hepion Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.133
Price to Book Ratio (EOD)Between0-10.346
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.012
Current Ratio (MRQ)Greater than13.322
Debt to Asset Ratio (MRQ)Less than10.354
Debt to Equity Ratio (MRQ)Less than10.547
Return on Equity (MRQ)Greater than0.15-0.651
Return on Assets (MRQ)Greater than0.05-0.421
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Hepion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.807
Ma 20Greater thanMa 502.127
Ma 50Greater thanMa 1002.291
Ma 100Greater thanMa 2002.491
OpenGreater thanClose1.300
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets25,003
Total Liabilities8,844
Total Stockholder Equity16,159
 As reported
Total Liabilities 8,844
Total Stockholder Equity+ 16,159
Total Assets = 25,003

Assets

Total Assets25,003
Total Current Assets21,269
Long-term Assets3,734
Total Current Assets
Cash And Cash Equivalents 19,284
Other Current Assets 1,985
Total Current Assets  (as reported)21,269
Total Current Assets  (calculated)21,269
+/-0
Long-term Assets
Property Plant Equipment 284
Intangible Assets 3,190
Long-term Assets Other 260
Long-term Assets  (as reported)3,734
Long-term Assets  (calculated)3,734
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,402
Long-term Liabilities2,442
Total Stockholder Equity16,159
Total Current Liabilities
Short-term Debt 112
Accounts payable 3,006
Other Current Liabilities 376
Total Current Liabilities  (as reported)6,402
Total Current Liabilities  (calculated)3,495
+/- 2,908
Long-term Liabilities
Capital Lease Obligations 242
Long-term Liabilities Other 1,904
Long-term Liabilities  (as reported)2,442
Long-term Liabilities  (calculated)2,145
+/- 297
Total Stockholder Equity
Common Stock0
Retained Earnings -213,568
Other Stockholders Equity 228,125
Total Stockholder Equity (as reported)16,159
Total Stockholder Equity (calculated)14,558
+/- 1,601
Other
Capital Stock1,696
Cash and Short Term Investments 19,284
Common Stock Shares Outstanding 3,838
Current Deferred Revenue2,908
Liabilities and Stockholders Equity 25,003
Net Debt -19,043
Net Invested Capital 14,464
Net Working Capital 14,867
Property Plant and Equipment Gross 645
Short Long Term Debt Total 242



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
76
9
2,643
2,001
1,005
8,965
9,500
5,377
2,854
10,646
6,750
13,107
8,816
16,068
11,760
18,385
14,121
11,253
9,396
7,975
14,381
8,189
7,905
23,339
21,073
20,433
20,612
24,084
20,364
48,645
123,757
119,753
111,602
103,552
103,552
83,566
69,697
60,244
60,244
36,502
25,003
25,00336,50260,24460,24469,69783,566103,552103,552111,602119,753123,75748,64520,36424,08420,61220,43321,07323,3397,9058,18914,3817,9759,39611,25314,12118,38511,76016,0688,81613,1076,75010,6462,8545,3779,5008,9651,0052,0012,643976
   > Total Current Assets 
76
9
2,628
1,982
893
8,851
9,362
5,244
2,720
10,518
6,626
7,895
3,613
10,859
6,559
13,193
8,937
6,062
4,149
2,741
9,155
2,968
1,913
17,389
15,185
14,389
14,389
18,169
14,352
42,634
117,745
113,673
105,500
97,452
97,452
79,534
65,670
56,496
56,496
32,762
21,269
21,26932,76256,49656,49665,67079,53497,45297,452105,500113,673117,74542,63414,35218,16914,38914,38915,18517,3891,9132,9689,1552,7414,1496,0628,93713,1936,55910,8593,6137,8956,62610,5182,7205,2449,3628,8518931,9822,628976
       Cash And Cash Equivalents 
76
3
2,510
1,818
735
8,792
8,901
4,563
1,791
9,832
5,957
7,404
3,028
10,552
6,137
12,983
8,779
5,954
3,998
2,580
9,032
2,832
1,683
17,149
14,864
13,923
13,923
17,562
13,711
40,727
115,449
110,091
98,731
91,349
91,349
71,708
59,145
51,189
51,189
30,522
19,284
19,28430,52251,18951,18959,14571,70891,34991,34998,731110,091115,44940,72713,71117,56213,92313,92314,86417,1491,6832,8329,0322,5803,9985,9548,77912,9836,13710,5523,0287,4045,9579,8321,7914,5638,9018,7927351,8182,510376
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
436
489
0
048943600000000000000000000000000000000000000
       Other Current Assets 
0
6
117
164
158
60
460
681
929
685
670
491
585
307
421
210
159
108
151
161
123
136
230
240
321
0
466
607
641
1,907
2,296
3,582
6,769
0
6,103
7,826
6,524
0
5,307
2,241
1,985
1,9852,2415,30706,5247,8266,10306,7693,5822,2961,90764160746603212402301361231611511081592104213075854916706859296814606015816411760
   > Long-term Assets 
0
0
16
19
111
113
138
133
134
129
123
5,212
5,203
5,209
5,201
5,192
5,184
1,928
5,247
5,234
5,226
5,221
5,991
5,950
5,889
6,044
6,223
5,915
6,011
6,011
6,012
6,080
6,101
6,101
6,101
4,032
4,028
3,748
3,748
3,740
3,734
3,7343,7403,7483,7484,0284,0326,1016,1016,1016,0806,0126,0116,0115,9156,2236,0445,8895,9505,9915,2215,2265,2345,2471,9285,1845,1925,2015,2095,2035,212123129134133138113111191600
       Property Plant Equipment 
0
0
16
15
56
62
87
81
83
77
72
81
74
80
72
68
62
57
46
42
37
32
790
749
700
855
855
725
660
665
666
599
545
456
456
275
183
132
132
61
284
28461132132183275456456545599666665660725855855700749790323742465762687280748172778381876256151600
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
0
0
0
0
0
0
0000001,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,87100000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,19000000000000
       Other Assets 
0
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,263
0
3,322
3,318
3,318
141
3,331
3,318
3,318
3,318
3,318
3,481
4,032
285
420
495
583
652
568
655
426
0
0
0
0004266555686525834954202854,0323,4813,3183,3183,3183,3183,3311413,3183,3183,32203,26300000000000000060
> Total Liabilities 
399
499
9,986
4,934
465
361
1,616
1,938
4,215
5,662
5,454
11,789
11,812
10,190
12,145
9,327
9,128
2,604
6,345
8,727
9,727
6,214
7,259
5,310
4,847
4,250
4,995
5,792
7,491
8,125
6,182
9,032
8,959
10,557
10,557
16,246
10,438
10,389
10,389
10,129
8,844
8,84410,12910,38910,38910,43816,24610,55710,5578,9599,0326,1828,1257,4915,7924,9954,2504,8475,3107,2596,2149,7278,7276,3452,6049,1289,32712,14510,19011,81211,7895,4545,6624,2151,9381,6163614654,9349,986499399
   > Total Current Liabilities 
399
499
260
459
465
361
1,616
1,938
4,215
3,761
4,289
5,084
5,162
3,224
2,474
2,945
2,811
2,604
2,563
5,000
5,653
2,850
3,457
1,798
1,505
1,252
1,609
2,603
3,956
4,662
2,867
7,102
7,082
8,206
8,206
13,377
7,489
7,886
7,886
7,674
6,402
6,4027,6747,8867,8867,48913,3778,2068,2067,0827,1022,8674,6623,9562,6031,6091,2521,5051,7983,4572,8505,6535,0002,5632,6042,8112,9452,4743,2245,1625,0844,2893,7614,2151,9381,616361465459260499399
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
10
0
0
0
0
0
0
0
2,000
2,070
1,440
2,093
981
521
0
267
275
275
280
388
286
285
0
267
177
106
0
54
0
112
1120540106177267028528638828027527526705219812,0931,4402,0702,00000000001000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,903
790
330
0
0
0
0
0
177
0
0
0
0
0
0
0
0
0
0
0000000000177000003307901,9030000000000000000000000
       Accounts payable 
28
56
188
244
213
114
1,313
1,481
3,196
3,162
3,441
4,252
4,397
2,303
1,563
1,627
1,483
1,557
1,732
2,079
2,216
748
707
283
675
492
492
972
1,297
3,722
1,662
3,087
1,794
2,446
2,446
8,912
2,627
2,666
2,666
4,191
3,006
3,0064,1912,6662,6662,6278,9122,4462,4461,7943,0871,6623,7221,2979724924926752837077482,2162,0791,7321,5571,4831,6271,5632,3034,3974,2523,4413,1623,1961,4811,3131142132441885628
       Other Current Liabilities 
371
443
72
215
251
247
303
457
1,019
599
847
821
765
921
911
1,318
1,328
1,047
831
920
1,367
661
657
535
308
0
851
1,356
2,384
660
817
3,729
5,004
2,988
5,494
4,288
4,757
366
366
3,483
376
3763,4833663664,7574,2885,4942,9885,0043,7298176602,3841,35685103085356576611,3679208311,0471,3281,3189119217658218475991,01945730324725121572443371
   > Long-term Liabilities 
28
56
9,726
4,475
213
114
1,313
1,481
3,196
1,901
1,166
6,706
6,650
6,966
9,672
6,382
6,318
4,950
3,782
3,727
4,074
3,364
3,802
3,512
3,342
2,998
3,385
3,188
3,535
3,463
3,315
1,930
1,876
2,351
2,351
2,869
2,949
2,503
2,503
2,455
2,442
2,4422,4552,5032,5032,9492,8692,3512,3511,8761,9303,3153,4633,5353,1883,3852,9983,3423,5123,8023,3644,0743,7273,7824,9506,3186,3829,6726,9666,6506,7061,1661,9013,1961,4811,3131142134,4759,7265628
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
177
0
0
0
0
0
0
0
0
0
0
0
0000000000017700000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,727
4,074
3,364
3,259
3,010
2,881
2,454
2,494
2,594
3,000
2,991
3,014
1,764
1,777
2,301
2,959
2,869
2,949
2,503
0
0
0
0002,5032,9492,8692,9592,3011,7771,7643,0142,9913,0002,5942,4942,4542,8813,0103,2593,3644,0743,7270000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,190
3,190
3,190
3,203
3,190
3,190
3,190
3,190
3,190
3,190
3,190
414
413
0
0
0
0
0
0
409
409
0
04094090000004134143,1903,1903,1903,1903,1903,1903,1903,2033,1903,1903,1900000000000000000000
> Total Stockholder Equity
-323
-490
-7,342
-2,933
540
8,604
7,884
3,439
-1,361
4,984
1,295
1,318
-2,996
5,878
-385
9,058
4,993
3,703
3,052
-752
4,654
1,975
645
18,029
16,227
16,183
15,617
18,292
12,873
40,520
117,575
110,721
102,643
92,995
92,995
67,320
59,259
49,856
49,856
26,373
16,159
16,15926,37349,85649,85659,25967,32092,99592,995102,643110,721117,57540,52012,87318,29215,61716,18316,22718,0296451,9754,654-7523,0523,7034,9939,058-3855,878-2,9961,3181,2954,984-1,3613,4397,8848,604540-2,933-7,342-490-323
   Common Stock
1
1
2
2
2
2
2
2
2
3
3
3
6
6
6
8
8
1
8
1
2
0
2
0
0
0
0
1
1
3
8
8
8
8
8
8
8
8
8
0
0
00888888888311000020218188666333222222211
   Retained Earnings -213,568-203,041-175,701-175,701-168,890-160,342-133,501-133,501-127,095-117,828-110,163-104,105-99,150-92,349-83,752-83,186-81,288-79,469-78,448-76,464-73,891-73,734-69,705-67,015-65,278-59,504-61,554-53,935-49,429-44,612-39,406-35,489-32,458-27,614-22,239-14,841-6,892-5,421-9,802-491-323
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77,462
76,651
77,327
95,773
95,798
97,651
104,459
0
0
142,911
226,022
226,834
0
0
0
0
0
0
223,944
227,806
0
0227,806223,944000000226,834226,022142,91100104,45997,65195,79895,77377,32776,65177,46200000000000000000000
   Treasury Stock00000000000000000000000000000000000000000
   Other Stockholders Equity 
-1
0
2,458
2,486
7,429
12,742
16,420
17,351
17,395
26,770
26,999
32,227
44,597
58,575
60,122
67,514
69,223
69,677
71,708
72,126
77,462
76,653
77,327
95,773
95,798
3
97,651
108,924
110,310
142,911
226,022
226,834
228,023
0
224,788
225,989
226,535
-90
223,944
227,806
228,125
228,125227,806223,944-90226,535225,989224,7880228,023226,834226,022142,911110,310108,92497,651395,79895,77377,32776,65377,46272,12671,70869,67769,22367,51460,12258,57544,59732,22726,99926,77017,39517,35116,42012,7427,4292,4862,4580-1



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-47,812
Operating Income-47,812-47,812
 
Operating Expense (+$)
Research Development37,713
Selling General Administrative10,099
Selling And Marketing Expenses-
Operating Expense47,81247,812
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-10
Net Interest Income-10
 
Pretax Income (+$)
Operating Income-47,812
Net Interest Income-10
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-47,562-48,072
EBIT - interestExpense = 0
-44,678
-44,678
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--47,562
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-47,562
Tax Provision--2,884
Net Income From Continuing Ops-44,678-44,678
Net Income-44,678
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net26010
 

Technical Analysis of Hepion Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hepion Pharmaceuticals Inc. The general trend of Hepion Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hepion Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hepion Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.49 < 1.89 < 2.8999.

The bearish price targets are: .

Tweet this
Hepion Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hepion Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hepion Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hepion Pharmaceuticals Inc. The current macd is -0.23995084.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hepion Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hepion Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hepion Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hepion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartHepion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hepion Pharmaceuticals Inc. The current adx is 22.98.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Hepion Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Hepion Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hepion Pharmaceuticals Inc. The current sar is 2.35721752.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hepion Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hepion Pharmaceuticals Inc. The current rsi is 26.81. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Hepion Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartHepion Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hepion Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hepion Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Hepion Pharmaceuticals Inc Daily Stochastic Oscillator ChartHepion Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hepion Pharmaceuticals Inc. The current cci is -176.40263224.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Hepion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartHepion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hepion Pharmaceuticals Inc. The current cmo is -60.41229975.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hepion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartHepion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hepion Pharmaceuticals Inc. The current willr is -94.96402878.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Hepion Pharmaceuticals Inc Daily Williams %R ChartHepion Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hepion Pharmaceuticals Inc. The current atr is 0.25658159.

Hepion Pharmaceuticals Inc Daily Average True Range (ATR) ChartHepion Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hepion Pharmaceuticals Inc. The current obv is 11,834,423.

Hepion Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartHepion Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hepion Pharmaceuticals Inc. The current mfi is 18.92.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Hepion Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartHepion Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hepion Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Hepion Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hepion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.807
Ma 20Greater thanMa 502.127
Ma 50Greater thanMa 1002.291
Ma 100Greater thanMa 2002.491
OpenGreater thanClose1.300
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hepion Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Hepion Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hepion Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hepion Pharmaceuticals Inc

I send you an email if I find something interesting about Hepion Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Hepion Pharmaceuticals Inc.

Receive notifications about Hepion Pharmaceuticals Inc in your mailbox!